Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

Recruiting now · Phase 4

Conditions studied: Steroid-refractory Acute Graft Versus Host Disease

In brief

The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).

Key facts

Study ID

NCT06462469

Run by

Novartis Pharmaceuticals

People needed

36

Starts

2024-07-04

Expected to finish

2028-02-17

Last updated by the study team

2025-11-25

Who can join

Age: 12 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Novartis Investigative Site — Guangzhou, Guangdong, China (enrolling)
• Novartis Investigative Site — Guangzhou, Guangdong, China (enrolling)
• Novartis Investigative Site — Zhengzhou, Henan, China (enrolling)
• Novartis Investigative Site — Wuhan, Hubei, China (enrolling)
• Novartis Investigative Site — Changchun, Jilin, China (enrolling)
• Novartis Investigative Site — Xian, Shanxi, China (enrolling)
• Novartis Investigative Site — Chengdu, Sichuan, China (enrolling)
• Novartis Investigative Site — Hangzhou, Zhejiang, China (enrolling)
• Novartis Investigative Site — Beijing, China (enrolling)
• Novartis Investigative Site — Beijing, China (enrolling)
• Novartis Investigative Site — Beijing, China (enrolling)
• Novartis Investigative Site — Beijing, China (enrolling)
• Novartis Investigative Site — Dalian, China (enrolling)
• Novartis Investigative Site — Fuzhou, China (enrolling)
• Novartis Investigative Site — Shanghai, China (enrolling)
• Novartis Investigative Site — Taian, China (enrolling)
• Novartis Investigative Site — Tianjin, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.